Category Archives: Diabetes

Sometimes its good to just be one of the gang.

This is certainly true for those dealing with Type 1 diabetes. And thats why Camp Hot Shots has become a favorite get-away destination for hundreds of youngsters ages 6-12 in central Nebraska since 2001.

Founded by Mary Lanning Heathcare and presented this year in partnership with Grace United Methodist Church, the two-day camp gives youngsters dealing with the disease a chance to bond with fellow diabetics without having to address those intrusive questions so often posed by their well-meaning but unmindful peers.

DeAnn Carpenter, program coordinator for Mary Lannings diabetes program, said the camp which is funded in part through donations from area organizations combines diabetes education and a host of fun activities to create an experience many campers have come to look forward to year after year.

More than 20 area children are taking part in this years long list of camp activities, which include: Boat rides and water play at Lake Hastings and Aquacourt Water Park, YMCA play, string art, balloon artist/magician Poppin Penelope, taekwondo, and more.

Its just a time for kids who have Type 1 diabetes to come together and realize theyre not alone, Carpenter said. A lot of them are the only ones in their school system or community who have Type 1 diabetes and maybe feel a little alone, having to take care of themselves. Its a time to bond and interact with people who have the same diagnosis as them.

For many campers, the camp has become an annual tradition, a place to bond with new found friends over shared activities. In some instances, it may be the only contact they have with their fellow diabetic companions each year.

For Braden Benjamin, 12, of Friend, this year marks his seventh go-around in the camp.

I like coming to the lake and swimming and tubing with my friends, he said. I get to see other diabetics that Im not around very often. I know most of them, but there are a few new ones every now and then.

I also like going to the YMCA. They have a bunch of different activities, like tennis and racquetball. You can go to the batting cage, and theres a pool there, too.

But its the camaraderie with fellow diabetics that makes the camp experience special to himself and fellow participants, he said.

The camp allows me to talk to other diabetics that I dont get to see very often. Its just nice to be around other people who share the disease that you have and know what it feels like. I hope to make more friends at the camp this year and get better at taking care of my diabetes. If my blood sugars are good I can pretty much do anything if I treat it beforehand.

Kordell Lovitt, 13, of Chapel, is attending the camp for the fourth straight year. Like most all of his fellow campers, he considers the lake activities the high water point of the two-day outing.

Im just swimming and having fun with my friends that I dont see a lot, he said. We talk about how we take care of our diabetes and how we treat our lows and highs. It (diabetes) is kind of stressful, but sometimes I just get over it.

And camp is a big reason for that, he said.

The others tell me what I dont do right and that I can do a better job of it, he said. I check on my blood sugars often here to keep them in range.

Having to explain himself and his limitations to non-diabetics day in and day out makes coming to camp seem even more of a getaway experience each year.

When people ask me, Why do you have to do this? its kind of weird and awkward, he said. Here, I dont have to tell them anything. I just want to have fun and pay attention to my diabetes.

Fourth-time camper Emmilly Berglund, 12, of Shelton said she felt right at home navigating the lakeside waters with friends of a feather.

I just like to come and see the other kids and talk to them about how everything is, she said. Its just enjoyable and relaxing to hang around other kids who have it (Type 1 diabetes). Im looking forward to the new activities they have this year like string art and going to the water park and learning new things.

Lee Wigert, 65, is a teacher at Hastings College and pastor of United Methodist churches in Juniata, Holstein and Kenesaw.

He, along with his wife, Diane, and son, Nate, 32, who has diabetes, have been donating their time giving boat and jet ski rides and sharing their back yard abutting Lake Hastings for the past decade.

Its just amazing the bonding experience that these children have, he said. The kids come back year after year and call you by name and you remember them. I spend about three days getting the house ready and tubes and trampoline blown up.

We make sure everybody gets on the boat. What they take away from this is that they know the adults care for them and are here to help them out.

See the rest here:
Diabetes camp educates, entertains - Hastings Tribune

Sally Hillerich Galla, Guest Contributor 3:13 p.m. ET June 15, 2017

Measuring blood sugar(Photo: Maya23K, Getty Images/iStockphoto)

It might be old-fashioned, but as a young child growing up in Kentucky, I was taught never to reveal my age. Yet to understand my story, you have to start with a number: Im 65, and Im incredibly fortunate to be alive.

At the age of 24, my doctor gave me six months to live, along with one last hope: an emergency surgery to treat the endometriosis which was threatening my life. Thankfully, that surgery was a success.

But my medical journey was just beginning.

In the weeks after my surgery, I lost 30 pounds, and my vision was getting increasingly blurry. A trip back to my doctor confirmed a new, equally troubling and unrelated diagnosis: Type-1 diabetes. At the time, the outlook for Type-1 patients was grim.

Like every person with Type-1 Diabetes, not a day goes by that I dont spend thinking about and treating my disease. But there are some risk factors beyond our control, notably that Medicare, unlike nearly every private insurance plan, wont pay for some treatments that helpus stay healthy.

To start, it helps to understand that Type-1 Diabetes keeps your pancreas from producing insulin, so those of us living with the disease must inject the right amount of insulin ourselves, using everything from needles to traditional insulin pumps. Youve probably seen these pumps; a patch is connected by tubes to a device clipped to your belt or placed in your pocket.

More: New health bill even worse threat for Kentuckians | Comment

More: Poverty, obesity fuel Ky's diabetes epidemic

More: Help list: Learn to avoid or manage diabetes

Devices like this come with significant drawbacks. They cant get wet, and patients with neuropathy and arthritis have a hard time connecting and re-connecting the tubes multiple times a day. However, they do have one major benefit: theyre covered by Medicare.

The device I use called an Omnipod isnt.

My Omnipod is a wireless pump; a small pod that can be worn nearly anywhere and is connected wirelessly to a device about the size of a cell phone, which doesnt have to be clipped to your clothing. Instead, it just has to be close by.

And this is where that bureaucratic thinking comes in. All other insulin pumps are paid for under Medicare Part B because theyre considered durable medical equipment.

But the Omnipod isnt.

Thats because the Omnipod is different. Each of the pods lasts three days. Once its supply of insulin is used up, you replace it with another. You keep the cell phone-sized transmitter, which connects wirelessly to each new pod. Yet even though it has been approved by the FDA for 12 years, Medicare still wont cover it.

Medicares non-coverage policy is in conflict with Congresss intent, which was to promote medical innovation. Back in 2003, they passed the Medicare Modernization Act, which made it clear: new technologies not covered under Part B should be covered under Part D, which covers medicines. Medicare hasnt used that authority to cover the Omnipod either. But it should.

Because Omnipod isnt covered under Medicare, the Federal government is forcing seniors like me to abandon the treatment we need.

Now Im fortunate: After paying out of pocket since I turned 65, I recently found out that my Express Scripts Medicare Advantage plan has decided to stop mirroring Medicares policy. Thanks to that decision, I will get the coverage I need. But millions of people arent as fortunate they rely on other Medicare and Medicare Advantage plans where Omnipod still isnt covered.

Every major diabetes patient and medical advocacy group agrees: There should be no reason why the Omnipod remains the only FDA-approved insulin pump not covered by Medicare. Theyve urged the Centers for Medicare and Medicaid Services to cover the Omnipod. And Im urging them now, too.

Medicare should cover Omnipod, because it is a critical part of my medical plan. I shouldnt be forced to lose it just because Ive turned 65and neither should any other senior.

A small business owner, Sally Hillerich Galla is a 40-year veteran of the health insurance industry who lives in Eastern Jefferson County with her husband, Patrick.

Read or Share this story: http://www.courier-journal.com/story/opinion/contributors/2017/06/15/expand-coverage-diabetes-treatment-sally-hillerich-galla/399244001/

Originally posted here:
Expand coverage for diabetes treatment | Sally Hillerich Galla - The Courier-Journal

Here are some data to file under Drugs do things that we dont expect. The SGLT-2 inhibitors are a class of diabetes medications that work by inhibiting the sodium/glucose transporter 2 protein in the kidneys. That keeps glucose from being reabsorbed there; instead, more of it is removed in the urine, and that lowers circulating glucose levels. One side effect, as you might imagine, is an increased risk of urinary tract infections, but overall, the class seems to have a lot of beneficial effects.

Too many beneficial effects, actually. One of the major drugs in this category, Jardiance (empagliflozin) from Boehringer and Lilly (NYSE:LLY), has recently been the subject of a big outcomes trial by the two companies. And the results were good the drug reduced cardiovascular mortality, all-causes mortality, and hospitalizations from heart failure. Good news! But when the team dug further into the data, things got weird. Youd think that these benefits would be due to reductions in glycosylated hemoglobin (HbA1c), lower LDL cholesterol, lower blood pressure, etc. But when they corrected for all these factors, the effects persisted.

Its quite clear that the results that we see from the drugmakers Empa-Reg Outcome studyincluding the 38% reduction in the risk of cardiovascular deathreally is not explained through these classical risk factors we have all been aware of for some decades now, Thomas Seck, Boehringers VP of clinical development and medical affairs for its primary care unit, said in an interview.

So what the heck is it explained by? At this point, no one knows. This is reminiscent of the situation with statins, whose good outcomes are not completely explained by their reduction of LDL levels. This should serve as a reminder that (1) there are a lot of biochemical mechanisms that we dont know about yet and (2) the ones that we know about arent necessarily as important as weve made them out to be.

Meanwhile, at the same ADA meeting where these results where released, J&J presented data on their own SGLT-2 inhibitor, Invokana (canaglifozin). And with this one, too, patients were notably less likely to suffer cardiovascular events, which is good news. But there was also an unexpected increased in the risk of amputation (which is already a risk in advanced Type II diabetes patients). This is not something thats turned up with the other SGLT-2 compounds so far, and is also a mystery.

We do not know what a new drug is going to do, not really, until its gone into a large patient population. And that means, most of the time, until its made it to the market. Clinical trials are absolutely necessary to clear out the biggest, most noteworthy problems, and will show you the biggest, most noteworthy benefits that can be shown in the time it takes to run the trial. But the longer, more subtle things (or the ones that happen in very low incidence) will only appear once the drug is out there in the real world, being taken by a large number of people under all kinds of conditions.

Disclosure: None.

Read more from the original source:
2 Diabetes Drug Mysteries - Seeking Alpha

A chemical called sulforaphane could be a new option for people with Type 2 diabetes who need help managing their blood sugar.

In a studyjust published inScience Translational Medicine, researchers randomized 97 people diagnosed with Type 2 diabetes to take a concentrated broccoli sprout extract containingsulforaphane once a day for 12 weeks or a placebo with the same regimen. All but three of the participants were taking metformin, a standard treatment for controlling blood sugar.

Broccoli at a market in Vienna. A new study shows yet another health benefit for the vegetable: A chemical it contains could help people with Type 2 diabetes manage blood sugar. Leonhard Foeger/Reuters

Tech & Science Emails and Alerts- Get the best of Newsweek Tech & Science delivered to your inbox

Glucose production was reduced among patients taking the ultraconcentrated sulforaphane. The compound improved fasting glucose and glycated hemoglobin, or HbA1c, an indicatorof blood sugar levels in obese patients with dysregulated Type 2 diabetes. And sulforaphane also showed a protective effect against some complications linked to diabetes, such as neuropathy and kidney failure.

How did the researchers light upon sulforaphane as a blood sugar manager? Genetics and math. Led by Annika Axelsson, of Lund University Diabetes Centre in Sweden, the scientists created a genetic profile for Type 2 diabetes based on 50 key genes, alterations of which are associated with the disease. They then screened 3,852 different compounds to find any that might reverse that genetic signature. Sulforaphane stood out.

Before studying the compound in humans, Axelsson and colleagues first gave sulforaphane to animals.In rats with diabetes, the compound, which occurs naturally in cruciferous vegetables, had the intended effect, reversing the genetic signature in the animals livers. The chemical also controlled blood sugar at a level comparable to metformin.

The human study that followed indicated that concentrated sulforaphane could be a viable treatment for Type 2 diabetes. Because up to 15 percent of the 300 million people with Type 2 diabetes worldwide cannot take metformin due to the risk of kidney damage, new ways to help patients manage blood sugar are needed. The researchers emphasize that high doses of sulforaphane cannot yet be recommended to patients as a drug treatment, the study results are a clear sign that the approach is worth pursuing.

View post:
Sulforaphane, a Chemical in Broccoli, May Help Diabetics Control Blood Sugar - Newsweek

From left, Rebecca Merriman (Medtronic), Melissa Louis (Medtronic), Shelley Blonheim (Insulin Pump User), Laura Cameron (Medtronic), Linda Hepner (Surrey Mayor), Neil Fraser (Medtronic) cut the ribbon to officially open a new Medtronic diabetes resource centre in Surrey. (Submitted photo)

Fraser Health says Surrey and Abbotsford have the largest proportion of diabetics in the region

SURREY Canadas first Medtronic Resource Centre for patients with diabetes held its grand opening in Surrey this Wednesday (June 14).

Located on the main floor of the City Centre 1 building across the street from Surrey Memorial Hospital, the new centre will serve as a one-stop shop for those with diabetes.

Its intended to be able to provide support in between clinic visits, explained Laura Cameron director of Medtronic Canadas Diabetes Group. To allow them to better utilize their technology so that they can have better support in managing their diabetes. We hope it will provide additional support to the clinics who will be doing some of the less-basic things with them. Well take care of some of the stuff in between.

The goal, she noted, is to elevate their ability to manage their disease and as a result, have better outcomes and fewer complications, thus, improving lives.

The new centre will offer insulin pump classes, lessons on CGM (continuous glucose monitoring) and educate patients on carb counting and best travel practices.

The centre, within the Innovation Boulevard health tech district, will also provide networking opportunities and one-on-one time with certified insulin pump trainers.

Cameron said Surrey was chosen as the location for their centre because of the high prevalence of diabetes in the city, and all of Fraser Health.

Its estimated that 29 per cent of British Columbians (or 1.5 million people) have either diabetes or pre-diabetes. Over the last decade, the province has seem a 74 per cent spike in the number of people diagnosed with diabetes and by 2027, its projected to grow by another 44 per cent.

According to Fraser Health, Surrey and Abbotsford have the largest proportion of diabetics within its region, which the health authority says may be due to the large South Asian populations living there.

Surrey diabetes specialist Dr. Chris Mahony said the centre has been much anticipated as a real-world solution to a real-world problem, offering post-marketing care of our clients on an intensive insulin regimen using Medtronic insulin pump technology.

He said the centre will raise the bar to a new level of support.

Jodie Steen has been living with Type 1 Diabetes for 31 years and started on her first insulin pump almost 17 years ago.

It has given me so much freedom and better blood sugar control than multiple daily injections, she aid. More recently, I have been wearing CGM on a regular basis which has resulted in the best A1C I have had in years.

Steen said she looks forward to having the access to experts at her convenience.

Cameron said thats why she does what she does to help people live better lives.

We hear stories about parents who had their first good night sleep since their child was diagnosed, as a result of being able to trust the pump, said Cameron. Thats why were so passionate. Its very rewarding.

The new Medtronics Resource Centre is located in the City Centre 1 building, located at 13737 96th Ave.

amy.reid@surreynowleader.com

The rest is here:
Canada's first Medtronic diabetes resource centre opens in Surrey - Surrey Now-Leader

People with diabetes do not get to pick and choose when they want to deal with it. Diabetes is an ongoing disease that requires 24/7 work. But does having diabetes stop people from living their life to the fullest?

There are probably many different answers to that question. According to Ginger Vieira, the author of, Dealing with Diabetes Burnout, on a daily basis, she tries to balance three things: diabetes, life, and happiness.

Diabetes occurs when the pancreas is unable to produce enough insulin to control the bodys blood sugar levels. Because of the daily testing of blood sugar and the management of the disease through medication, activity and diet, people with diabetes can feel, as described by Linda Von Wartburg in Diabetes Health, ground down by the appalling endlessness of self-care. This causes burnout, which, in the context of diabetes, means ignoring blood sugar levels and neglecting the diet. This can harm a persons health and contribute to diabetes complications.

Experts advise making good enough the goal, rather than perfection when it comes to blood sugar readings. Striving for perfection can cause frustration, which can lead to people abandoning checking their sugar in fear of another bad reading. Other ways to avoid burnout include: learning more about diabetes, working with doctors to come up with a plan when you are overwhelmed by self-care, and joining diabetes support groups.

Although a person with diabetes may get burned out, they dont have to stay that way. Seeking help from health care providers, family and friends can get them back to living their life to the fullest.

Resources: Vieira, G. (2014). Dealing with diabetes burnout: how to recharge and get back on track when you feel frustrated and overwhelmed living with diabetes. New York: Demos Health. Von Wartburg, L. (2007). Diabetes Burnout. Diabetes Health, 16(3), 27-29. http://www.joslin.org/info/avoid_diabetes_burnout.html http://www.everydayhealth.com/hs/type-2-diabetes-live-better-guide/maintain-motivation/ http://www.diabetes.co.uk/emotions/diabetes-burnout.html

Content for this segment was created by Sidney Brockmeyer as part of a project for SC301: Foundations of Health Communication, taught by Ms. Clubbs.

Read the rest here:
Diabetes Burnout - KRCU

For about a week, Griffin Kyes will get to be a normal child at summer camp. He'll do all the traditional camp activities: running through the woods, swimming, watching skits and playing in the GaGa ball pit his favorite.

Along the way, Kyes will also master how to control his Type 1 diabetes.

"I've learned that you need to control your diabetes or else your body could get really harmed," said the soon-to-be fifth-grader at Pioneer Elementary School in Bismarck.

This will be Kyes third time at Camp Sioux, which is for children ages 8 to 15 who have diabetes. It's the only camp like it in the state, located in Park River, just northwest of Grand Forks.

Camp Sioux is sponsored by various organizations, including several Lions Clubs, such as the one in Mandan. The American Diabetes Association runs the camp, according to Carol Holten, associate manager of community health strategies for the Midwest Division of the ADA.

"We just want them to be normal kids and know that their diabetes won't hold them back," Holten said.

The kids do this while also learning independence. There aren't any formal educational sessions or classes, but instead "teachable moments," Holten said.

There will be dietitians to help count carbs. Some of the children will learn to take an insulin shot for the first time.

Kyes was diagnosed with Type 1 diabetes when he was 4 years old. His mother, Lisa Rask, said the chronic disease doesn't run in the family, and she began noticing Kyes' symptoms, such as being constantly thirsty, weak and wetting the bed,when he was younger.

It was super hard to drop him off the first year when a kid is diabetic you cant just let them go to a party or sleepover, it doesnt work like that," she said. "When you walk into camp, you have a parent meeting and they line up all the nurses and doctors, and you just feel better."

Behavioral Risk Factor Surveillance System, 2014

In 2014, about 49,000 adults in North Dakota were living with diagnosed diabetes, and an estimated 37 percent of the population, or more than 202,000 people, had prediabetes.

There are two types of diabetes: Type 1 is most common in people under age 20, and it occurs when insulin-producing cells of the pancreas are damaged. In this instance, little or no insulin is produced, and patients need insulin injections to control their blood sugar.

Type 2 diabetes is diagnosed in people who produce insulin, but not enough. This type can be managed by controlling a person's weight, diet, regular exercise or by taking oral medicine or insulin injections.

There are some serious complications associated with diabetes, including lower limb amputation, blindness, kidney failure and cardiovascular disease.

Holten said 150 children plan to attend Camp Sioux this year, up from 134 in 2016. She said the increase in children attending the camp can be attributed to a general rising trend in the number of children with diabetes, but also to more doctors getting the word out to newly diagnosed patients.

Such gatherings aim to help children control the disease while also helping them meet others who are experiencing the same things. Many of the camp counselors are former campers.

"Many of the younger kids aspire to (become a counselor), and the older kids love being able to be in that staff position," Holten said.

KateyNick, a nurse and diabetes educator at Sanford Health in Bismarck, was diagnosed with Type 1 diabetes at age 3.

"I don't remember it any other way," said Nick, 26, who has gone to Camp Sioux on and off since she was 8 years old.

Nick has been a camper, counselor and, this year, she'll go back as a nurse.

"Growing up, I didn't really want to take care of myself. I wanted to be a normal teenager; eat what I wanted," said Nick, who struggled to control her diabetes.

But the camp helped her feel normal, and she's made some lifelong friends along the way.

"It helps kids really learn that they're not so different. They have this chronic disease, but it's manageable," Nick said.

Read more:
Children with diabetes find comfort at camp - Bismarck Tribune

By Garrett Ohlmeyer Staff Writer

An 11-year-old from Raceland will be joining about 160 other kids and celebrities in Washington, D.C., next month to advocate continued support of Type 1 diabetes research.

Rory Monier was diagnosed with Type 1 diabetes in November 2007 when he was just 2 years old.This fall, he will be a seventh-grader at Lockport Middle School, and he doesnt let his disease stop him from being a normal kid. Monier plays on a soccer team, plays drums in his middle school band and is involved in school clubs.

He said he was happy to be selected by the Juvenile Diabetes Research Foundation to represent those who have the disease and to share his family's story with Congress.

I want my congressman to know that kids battling Type 1 diabetes have a constant reminder that we have diabetes every time we eat or want to take part in activities, Monier said. We have daily schedules that are important in saving our lives.

The children and other delegates will share personal experiences and explain the daily struggles associated with living with the disease. The goal is to push for continued support of the Special Diabetes Program, which pays for research projects related to the disease. The program is set to expire Sept. 30.

Nine celebrities will join the children in the event. They include athletes and actors.

Type 1 diabetes is a condition that causes a person's pancreas to stop producing insulin, a hormone that enables people to gain energy from food. This happens when the immune system attacks and destroys cells in the pancreas that create the insulin.

Since Moniers diagnosis, his family has been involved with the foundation and has raised about $123,000 over the past nine years, said his mother, Kristy Monier.

Rory will travel to the nations capitol to participate in the Juvenile Diabetes Research Foundation Childrens Congress July 24-26. He was selected out of six applicants in Louisiana and more than 1,300 throughout the country.

-- Staff Writer Garrett Ohlmeyer can be reached at (985) 850-1149 or garrett.ohlmeyer@houmatoday.com. Follow him on Twitter @GOhlmeyer.

Continued here:
Raceland boy to advocate diabetes research - Daily Comet

BBC News

Diane Abbott reveals she has type 2 diabetes BBC News Diane Abbott has revealed she has Type 2 diabetes and that the condition is what forced her to take a break from the election campaign. The shadow home secretary told the Guardian she was diagnosed with the condition two years ago and it was "out of ... Diane Abbott reveals diabetes was 'out of control' during election campaignTelegraph.co.uk Diane Abbott reveals she has diabetes and blames illness for car-crash interviews during election campaignThe Sun Diane Abbott reveals diabetes cut short her election campaign - and caused radio mix-upMirror.co.uk The Times (subscription) -Evening Standard -ITV News all 11 news articles »

Read the rest here:
Diane Abbott reveals she has type 2 diabetes - BBC News

Johnson & Johnson still faces troubles over its Invokana diabetes drug. (Kadmy-Fotolia/stock.adobe.com)

Johnson & Johnson's (JNJ) diabetes drug, Invokana, cut down on cardiovascular events during a long-termstudy but Eli Lilly (LLY) stands to benefit most asdoctors steer clear of the medication on worries it increased the risk of amputation.

The study, dubbed Canvas, was presented late Monday. In it, Dow stock Johnson & Johnson said Invokana reduced the risk of cardiovascular death, nonfatal heart attack and nonfatal stroke by 14% vs. a non-drug placebo.

Additional analysis showed that Invokana lowered the risk of hospitalization for heart failure by 33%. Invokana also delayedthe progression of albuminuria the presence of a specific chemical in the urine indicating kidney disease.

RBC analyst Glenn Novarro says the Canvas study is unlikely to reverse the negative trajectory of Invokana sales. In the first quarter, Invokana and Invokamet sales dropped 17% year over year. For 2017, Novarro forecasts a 6% dip in sales to $1.2 billion.

Eli Lilly, on the other hand, will benefit from Johnson & Johnson's study as Merck (MRK) trails, analysts say.Lilly's Jardiance is a SGLT2 inhibitor, which works by helping the kidneys to lower blood glucose levels. Merck's Januvia is a DPP-4, which blocks glucagon release, triggering insulin secretion.

"Validated cardiovascular benefits should boost the SGLT2 class," Credit Suisse analyst Vamil Divan wrote. In a similar study, Lilly's Jardiance also showed a 14% benefit on cardiovascular outcomes. Jardiance also cut the risk of cardiovascular death and all mortality.

Even without the Canvas study, Lillywaspoised to grab a chunk of Invokana's sales after the Food and Drug Administration required Johnson & Johnson to warn physicians of the potential for amputation associated with Invokana.Invokana doubled the risk of amputation in a recent study.

Experts cited by Leerink analyst Seamus Fernandez say the amputation worry could be the "biggest differentiating factor" in physicians' decision to prescribe Jardiance over Invokana, as both show a similar cardiovascular benefit in diabetes patients.

At the close on the stock market today, Johnson & Johnson stock ticked up 0.2% to finish the regular trading session at 132.02. Lilly stock added 0.4% to 81.25 and shares of diabetes drugmaker Merck dipped 1% to end the day at 63.27.

IBD'S TAKE:Johnson & Johnson stock has an IBD Composite Rating of 77, meaning it outperforms more than three-quarters of all stocks in terms of key growth metrics. For more of IBD's ratings visit IBD Stock Checkup.

Meanwhile, the DPP-4 class of diabetes drugs, which includes Merck's Januvia, could face incremental pressure, Credit Suisse's Divan said.

"Over time, however, we expect the enthusiastic response to the Canvas efficacy data driving use of the SGLT2 class earlier in the course of treatment, while concurrently pushing the DPP-4s further back," he said in a note to clients.

Merck and Pfizer (PFE), a Dow stock, are jointly working on an SGLT2 inhibitor called ertugliflozin.Regulators could approve the drug in December, but it won't have data on cardiovascular outcomes for several years.Pfizer will take a chunk of thosesales, meaning a shift from Januvia toertugliflozin will be a net negative for Merck.

RELATED:

Lilly Could Grab Diabetes Share From Dow's J&J On Amputation Woes

AbbVie Expects Rivals To Chip Away At Its Biggest Drug Franchise

Dow's Pfizer Faces Challenges As Roche, J&J, Lilly Loom

6/13/2017 Get the latest news and analysis on the Dow Jones Industrial Average and its 30 component stocks.

6/13/2017 Get the latest news and analysis on the Dow Jones...

More here:
Dow's J&J Hosted A Diabetes Study And Lilly Will Benefit Most - Investor's Business Daily